Granulocyte colony stimulating factor biobetter - UBI Pharma
Alternative Names: Long acting GCSF - UBI Pharma; UB 853Latest Information Update: 25 Sep 2024
At a glance
- Originator UBI Pharma
- Class Antineoplastics; Biobetters; Chemoprotectants; Granulocyte colony-stimulating factors; Recombinant fusion proteins
- Mechanism of Action Granulocyte colony stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Neutropenia
Most Recent Events
- 25 Sep 2024 Preclinical trials in Neutropenia in Taiwan (Parenteral), prior to September 2024 (UBI Pharma pipeline, September 2024)
- 20 Dec 2023 Early research in Neutropenia in Taiwan (Parenteral) (UBI Pharma pipeline, December 2023)
- 21 Nov 2023 UBI Pharma has patent protection for immunoglobulin fusion proteins in USA